Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin's Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
13.12.2021 - ALPHA Trials Demonstrate Potential for AlloCAR T Therapy to be a Safe and Durable Alternative to Autologous Cell Therapy in CAR T Naïve PatientsAlloCAR T Therapy was Associated with Consistent and Manageable Safety with No DLTs or GvHD; Low Rates of ...
United States Christine Cassiano Allogene Allo Rafael Amado Allogene Therapeutics Inc American Society Of Clinical Oncology
Source: wallstreet-online.de